Respiratory syncytial virus (RSV) is an important cause of respiratory disease among older adults and those with chronic conditions and contributes substantially to healthcare use in Italy. The availability of effective RSV vaccines creates an opportunity to reduce RSV-related morbidity, mortality, and healthcare costs in high-risk older populations. This study evaluates the projected public health impact and cost-effectiveness of a single-dose mRNA-1345 vaccine compared with no vaccination in Italian high-risk adults aged 60–74 years and all adults aged ≥75 years.
The authors developed a static decision-analytic model to project clinical and economic outcomes over a 5-year time horizon. Economic outcomes were estimated from the perspective of the Italian National Health Service (Servizio Sanitario Nazionale, SSN). The model compared a single-dose vaccination strategy using mRNA-1345 to no vaccination for the defined target groups.
Model inputs were drawn primarily from recent Italian epidemiological, clinical, and economic evidence with supplementation from published international sources when Italian data were not available. The analysis included projections of healthcare encounters, deaths, antibiotic prescriptions, costs to the SSN, and health outcomes measured as quality-adjusted life years (QALYs).
To assess uncertainty, the study conducted deterministic, probabilistic, and scenario analyses testing alternative assumptions and input ranges. These sensitivity analyses evaluated the stability of the cost-effectiveness conclusions under plausible variations in model parameters.
The model incorporated Italian incidence and healthcare utilization estimates for RSV among older adults, probabilities of outpatient visits, emergency department encounters, hospitalizations, and RSV-attributable mortality. Economic inputs represented costs borne by the SSN for outpatient care, emergency department visits, hospitalizations, and other relevant services. Where Italian data were lacking, the authors used published international evidence consistent with best available sources.
Health outcomes were aggregated as QALYs lost to RSV and QALYs gained through vaccination. The analysis also quantified antibiotic prescriptions attributable to RSV and the resulting potential reductions following vaccination.
Over the 5-year analytic horizon, vaccination with mRNA-1345 in the specified target populations was projected to avert more than 19,800 hospitalizations and approximately 4,000 emergency department visits. The model estimated around 381,000 fewer outpatient visits and approximately 6,000 RSV-attributable deaths compared with no vaccination. Vaccination was also projected to prevent about 212,000 antibiotic prescriptions that would otherwise be associated with RSV disease.
These reductions represent the modeled direct clinical benefits in healthcare utilization and mortality for the high-risk 60–74 and all ≥75 age groups in Italy under the vaccination strategy evaluated.
The vaccination program’s total incremental cost to the SSN was reported as €1,143 million over five years. The strategy produced an additional 47,477 QALYs relative to no vaccination. Dividing incremental costs by incremental QALYs yielded an incremental cost-effectiveness ratio (ICER) of €24,078 per QALY gained.
The reported ICER falls below the commonly referenced willingness-to-pay range cited in the study context (€33,000–40,000 per QALY). Based on these base-case results, the authors conclude that a single-dose mRNA-1345 vaccination program for the targeted older adult groups would be considered cost-effective from the SSN perspective.
The study performed deterministic, probabilistic, and scenario analyses to explore the influence of uncertainty in model inputs and assumptions on outcomes. The authors report that sensitivity analyses confirmed the robustness of the cost-effectiveness results, although detailed parameter-level impacts and probabilistic distributions are provided in the electronic supplementary materials accompanying the manuscript.
Readers should consult the supplementary materials for full specification of parameter ranges, probabilistic analysis methods, and scenario descriptions used to test alternative assumptions.
Under the assumptions and inputs used, vaccination with mRNA-1345 in high-risk adults aged 60–74 years and all adults aged ≥75 years in Italy is projected to provide substantial public health benefits, including tens of thousands fewer hospitalizations and thousands fewer deaths over five years, and to be cost-effective from the SSN perspective with an ICER of €24,078 per QALY gained.
These results suggest that implementing a targeted RSV vaccination program using mRNA-1345 could reduce healthcare burden and provide good value for money in the Italian older adult population evaluated. Policymakers should consider local budget impact, implementation logistics, and population uptake when interpreting these modeled findings.
The analysis was conducted by Inizio Ignite Putnam under the direction of Moderna and funded by Moderna, Inc. Several authors are employees of Inizio Ignite Putnam, RTI Health Solutions, or Moderna; one author received honoraria from Moderna for scientific consultancy related to this study. These competing interests are disclosed in the manuscript.
The authors report that all data generated are available in the electronic supplementary materials accompanying the manuscript. The analysis used published data only and did not require additional ethical review; no new human or animal studies were performed by the authors.
(For detailed tables, parameter values, and full sensitivity analysis results, consult the supplementary files provided with the preprint.)